Why Is AGIOS PHARMACEUTICAL (AGIO) Stock Down Today?

AGIO stock is down 6.74% at $37.36 following the company’s announcement that it will discontinue development of tebapivat for sickle cell disease after a Phase 2 trial. The decision shifts focus to mitapivat, which is under FDA Priority Review for its sNDA, but the news has caused concern among investors. The stock has fallen for multiple reasons, including the termination of a key program and the broader market context.

What Happened

Agios Pharmaceuticals announced it will stop development of tebapivat, an oral pyruvate kinase activator, for sickle cell disease after the Phase 2 trial failed to meet expectations. The 12-week study involved 59 patients, and the company cited the outcome as the reason for discontinuation. Mitapivat remains a key focus, with a PDUFA goal date of Nov. 1, 2026. Despite this, the decision to abandon tebapivat has raised questions about the company’s pipeline depth and future growth prospects. The stock has dropped sharply in response, reflecting investor disappointment.

What The Data Shows

AGIO has fallen 7.6% over the past eight sessions, from $40.96 to $37.85. The stock currently trades within its 52-week range of $22.24 to $46.00. The company reported a revenue increase of 78.3% in the trailing twelve months but remains unprofitable with an EPS of -7.25. The recent insider transaction includes a $151K sale by the Chief Medical Officer on July 1, 2026. Congressional activity includes a buy of $1,001, $15,000 by Rep. Gilbert Cisneros on December 11, 2025.

What To Watch

Investors should monitor the FDA’s decision on mitapivat’s sNDA, with a PDUFA date of Nov. 1, 2026. Broader market sentiment and coverage from analysts will also be key as the stock continues to face pressure.